GALT: Galectin Therapeutics, Inc.
About
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Current Value
$2.751 Year Return
Current Value
$2.751 Year Return
Key Details
Market Cap
$172.91M
P/E Ratio
-3.78
1Y Stock Return
41.28%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
-1.8
Strategies that include GALT
Stock's related to GALT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DXYZ | 28.24% | - | - | 0.00% |
| GHM | 28.11% | $464.78M | +132.21% | 0.00% |
| AMTX | 26.81% | $195.46M | -16.56% | 0.00% |
| AYI | 26.58% | $9.78B | +75.10% | 0.19% |
| BCC | 26.51% | $5.31B | +32.92% | 0.59% |
| ABUS | 26.27% | $661.33M | +90.71% | 0.00% |
| ALXO | 25.94% | $64.87M | -86.56% | 0.00% |
| SPOT | 25.57% | $90.80B | +159.59% | 0.00% |
| XASAX | 25.38% | - | - | 0.20% |
| CDE | 25.33% | $2.66B | +143.96% | 0.00% |
| KEX | 24.79% | $7.36B | +65.91% | 0.00% |
| PRIM | 24.58% | $4.37B | +163.90% | 0.30% |
| OPRX | 24.53% | $75.16M | -58.02% | 0.00% |
| SUP | 24.14% | $69.04M | -13.41% | 0.00% |
| MYRG | 23.71% | $2.35B | +19.41% | 0.00% |
| SII | 23.49% | $1.11B | +41.80% | 2.41% |
| AG | 23.40% | $2.01B | +21.76% | 0.28% |
| AVD | 23.04% | $182.80M | -32.45% | 1.42% |
| CGNX | 22.96% | $6.73B | +6.19% | 0.78% |
| PNTG | 22.94% | $1.09B | +133.90% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CPNG | <0.01% | $43.51B | +49.69% | 0.00% |
| REYN | -0.01% | $5.79B | +3.76% | 3.35% |
| BALY | -0.01% | $726.31M | +54.50% | 0.00% |
| CMG | 0.01% | $80.02B | +33.62% | 0.00% |
| ATUS | -0.02% | $1.10B | -0.42% | 0.00% |
| LPTX | -0.02% | $103.46M | +10.66% | 0.00% |
| GH | 0.03% | $3.79B | +33.86% | 0.00% |
| PBR | -0.04% | $52.88B | -8.22% | 5.68% |
| RDWR | 0.05% | $960.27M | +53.82% | 0.00% |
| LUNA | 0.05% | $55.69M | -71.48% | 0.00% |
| AGYS | 0.05% | $3.44B | +39.55% | 0.00% |
| ACN | 0.09% | $221.17B | +7.17% | 1.52% |
| IART | -0.09% | $1.77B | -40.82% | 0.00% |
| NKE | -0.11% | $110.02B | -30.63% | 2.01% |
| OCX | -0.11% | $42.93M | -36.09% | 0.00% |
| SSSS | -0.12% | - | - | 0.00% |
| GORV | 0.13% | $12.75M | -84.80% | 0.00% |
| QNTM | 0.13% | $9.19M | -94.36% | 0.00% |
| USM | -0.14% | $5.35B | +41.82% | 0.00% |
| MED | 0.17% | $189.44M | -73.66% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UTZ | -14.62% | $1.37B | +26.87% | 1.41% |
| GL | -14.39% | $9.18B | -8.60% | 0.86% |
| CHD | -14.37% | $27.18B | +19.50% | 1.03% |
| PRPO | -14.36% | $9.10M | -13.65% | 0.00% |
| SJM | -13.93% | $11.91B | -0.25% | 3.82% |
| PEP | -13.86% | $215.02B | -6.60% | 3.35% |
| CPB | -12.69% | $12.96B | +7.08% | 3.40% |
| K | -12.11% | $27.77B | +52.50% | 2.79% |
| VSTA | -11.95% | $204.94M | -39.33% | 0.00% |
| PG | -11.93% | $402.15B | +14.14% | 2.33% |
| CL | -11.71% | $76.48B | +22.25% | 2.12% |
| STG | -11.68% | $35.67M | +7.92% | 0.00% |
| NOC | -11.03% | $71.54B | +4.23% | 1.60% |
| GME | -10.72% | $11.76B | +119.68% | 0.00% |
| FDS | -10.68% | $18.29B | +5.24% | 0.84% |
| MAGN | -9.94% | $638.97M | -3.42% | 0.00% |
| CHRW | -9.91% | $12.89B | +32.52% | 2.24% |
| SKM | -9.88% | $8.53B | -0.67% | 6.32% |
| FATBB | -9.72% | $81.94M | -12.91% | 11.69% |
| RNR | -9.68% | $13.74B | +23.09% | 0.58% |
ETF's related to GALT
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| QQA | 48.70% | $135.01M | 0% |
| RSPA | 42.65% | $273.87M | 0% |
| IJT | 29.02% | $6.64B | 0.18% |
| SLYG | 28.47% | $3.69B | 0.15% |
| IWC | 28.37% | $933.99M | 0.6% |
| EFAA | 27.84% | $117.38M | 0% |
| ISCG | 27.69% | $640.00M | 0.06% |
| FIDU | 27.45% | $1.25B | 0.084% |
| SECT | 27.27% | $2.00B | 0.77% |
| XSMO | 27.17% | $1.25B | 0.39% |
| FMDE | 27.13% | $2.02B | 0.23% |
| XLI | 26.98% | $21.95B | 0.09% |
| PSC | 26.94% | $702.17M | 0.38% |
| CALF | 26.88% | $8.93B | 0.59% |
| DCOR | 26.86% | $1.01B | 0.14% |
| IWM | 26.86% | $75.73B | 0.19% |
| DFAC | 26.85% | $32.50B | 0.17% |
| GSSC | 26.85% | $529.86M | 0.2% |
| SFYX | 26.83% | $105.21M | 0.06% |
| RDVI | 26.78% | $1.52B | 0.75% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SHAG | -0.05% | $33.13M | 0.12% |
| EMHC | -0.07% | $284.53M | 0.23% |
| GBIL | -0.11% | $5.60B | 0.12% |
| IBHD | 0.11% | $327.80M | 0.35% |
| FLRT | 0.12% | $401.26M | 0.6% |
| VDC | -0.13% | $7.09B | 0.1% |
| GSG | -0.17% | $914.42M | 0.75% |
| IBDU | -0.17% | $1.95B | 0.1% |
| HIGH | -0.20% | $302.78M | 0.51% |
| FLTR | -0.21% | $1.79B | 0.14% |
| IBDQ | 0.22% | $2.89B | 0.1% |
| COMT | -0.26% | $829.06M | 0.48% |
| BILZ | -0.27% | $563.02M | 0.14% |
| FSTA | 0.28% | $1.20B | 0.084% |
| DBC | 0.31% | $1.39B | 0.87% |
| TDTT | 0.32% | $1.84B | 0.18% |
| LDSF | 0.34% | $131.03M | 0.75% |
| DBA | 0.34% | $755.88M | 0.93% |
| VTIP | -0.40% | $11.71B | 0.04% |
| CQQQ | -0.43% | $733.30M | 0.65% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -16.44% | $67.98M | 0.59% |
| BTAL | -14.37% | $388.04M | 1.43% |
| DFNM | -13.71% | $1.40B | 0.17% |
| SOYB | -12.39% | $27.32M | 0.22% |
| VIXY | -12.25% | $195.31M | 0.85% |
| IBMM | -10.82% | $391.28M | 0.18% |
| CGSM | -10.47% | $514.53M | 0.25% |
| TOTL | -10.26% | $3.31B | 0.55% |
| AGGH | -10.24% | $253.02M | 0.33% |
| SMMU | -9.43% | $624.12M | 0.35% |
| SEIX | -9.37% | $268.81M | 0.62% |
| HTAB | -8.90% | $437.10M | 0.4% |
| PWZ | -8.74% | $697.36M | 0.28% |
| BUXX | -8.73% | $162.67M | 0.25% |
| HYMB | -8.70% | $2.81B | 0.35% |
| HDRO | -8.62% | $164.26M | 0.3% |
| CORN | -8.41% | $61.12M | 0.2% |
| MUNI | -8.20% | $1.73B | 0.35% |
| FMB | -8.14% | $2.03B | 0.65% |
| CGMU | -8.02% | $2.53B | 0.27% |
News
Yahoo
Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trialsApproximately a third of patients with MAS
Yahoo
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin
Finnhub
Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30,...
Finnhub
NORCROSS - Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in...
Yahoo
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, C
Yahoo
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.